晚期肿瘤患者中纳武利尤单抗240毫克固定剂量与3毫克每千克给药方案获益-风险特征的评估
该研究基于群体药代动力学建模与临床安全性数据,比较纳武利尤单抗240毫克固定剂量与3毫克每千克每2周方案在晚期肿瘤患者中的获益-风险特征。结果显示240毫克每2周暴露与3毫克每千克每2周相似,安全性与疗效预测相近,支持监管决策用于剂量调整而无需独立临床研究。
要点
- 240毫克固定剂量基于约80千克中位体重时与3毫克每千克剂量等效而选定。
- 模拟人群中240毫克每2周暴露与3毫克每千克每2周相似。
- 体重或暴露四分位与不良事件频率或严重程度间未显示有临床意义的关系。
核心结论
- 基于群体药代动力学建模、已建立的疗效与安全性平坦暴露-反应关系及临床安全性,纳武利尤单抗240毫克每2周的获益-风险特征与3毫克每千克每2周相当。
研究设计与样本
- 采用定量临床药理学方法,比较纳武利尤单抗240毫克固定剂量与3毫克每千克每2周方案在晚期肿瘤患者中的获益-风险特征。
- 240毫克固定剂量基于其与3毫克每千克剂量在纳武利尤单抗项目中患者约80千克中位体重时等效而选定。
主要发现
- 模拟人群中240毫克每2周的纳武利尤单抗中位暴露及其分布与3毫克每千克每2周相似。
- 安全性分析未显示体重或纳武利尤单抗暴露四分位与不良事件频率或严重程度之间有临床意义的关系。
- 在3毫克每千克每2周或240毫克每2周固定剂量达到的纳武利尤单抗暴露范围内,预测的安全性与疗效相似。
临床怎么用
- 定量临床药理学方法为剂量调整的监管决策提供了证据,无需开展独立临床研究。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Nivolumab 3 mg/kg every 2 weeks (Q2W) has shown benefit versus the standard of care in melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC). However, flat dosing is expected to shorten preparation time and improve ease of administration. With knowledge of nivolumab safety, efficacy, and pharmacokinetics across a wide dose range in body weight (BW) dosing, assessment of the benefit-risk profile of a 240-mg flat dose relative to the approved 3-mg/kg dose was approached by quantitative clinical pharmacology. PATIENTS AND METHODS: A flat dose of 240 mg was selected based on its equivalence to the 3-mg/kg dose at the median BW of ∼80 kg in patients in the nivolumab program. The benefit-risk profile of nivolumab 240 mg was evaluated by comparing exposures at 3 mg/kg Q2W and 240 mg Q2W across BW and tumor types; clinical safety at 3 mg/kg Q2W by BW and exposure quartiles in melanoma, NSCLC, and RCC; and safety and efficacy at 240 mg Q2W relative to 3 mg/kg Q2W in melanoma, NSCLC, and RCC. RESULTS: The median nivolumab exposure and its distribution at 240 mg Q2W were similar to 3 mg/kg Q2W in the simulated population. Safety analyses did not demonstrate a clinically meaningful relationship between BW or nivolumab exposure quartiles and frequency or severity of adverse events. The predicted safety and efficacy were similar across nivolumab exposure ranges achieved with 3 mg/kg Q2W or 240 mg Q2W flat dose. CONCLUSION: Based on population pharmacokinetic modeling, established flat exposure-response relationships for efficacy and safety, and clinical safety, the benefit-risk profile of nivolumab 240 mg Q2W was comparable to 3 mg/kg Q2W. The quantitative clinical pharmacology approach provided evidence for regulatory decision-making on dose modification, obviating the need for an independent clinical study.
引用
- Zhao X, Suryawanshi S, Hruska M, et al. Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors. Ann Oncol. 2017. PMID: 28520840. doi:10.1093/annonc/mdx235
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。